Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity

Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies

(2017) Andrzej J. Jakubowiak et al.   Hematology

Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity

(2017) Carol Chen-Scarabelli et al.   EBioMedicine

Management of Carfilzomib-Associated Cardiac Adverse Events

(2016) Joseph Mikhael   Clinical Lymphoma Myeloma & Leukemia

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?

(2016) A Rosenthal et al.   Blood Cancer Journal

‘Real-life’ experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors

(2015) Sophia Danhof et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Patterns of Cardiac Toxicity Associated With Irreversible Proteasome Inhibition in the Treatment of Multiple Myeloma

(2015) E. Wilson Grandin et al.   JOURNAL OF CARDIAC FAILURE

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib

(2015) S Atrash et al.   Blood Cancer Journal

A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma

(2014) N. Lendvai et al.   BLOOD

Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring

(2014) Ajai Chari et al.   BMC CANCER

Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability

(2014) Erika Assarsson et al.   PLoS One

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

(2013) D. Siegel et al.   HAEMATOLOGICA